Nephrotic Syndrome Market Report 2026

The nephrotic syndrome market size has grown rapidly in recent years. It will grow from $0.96 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to high prevalence of diabetes and hypertension, reliance on steroids for treatment, limited diagnostic awareness, gradual adoption of dialysis technologies, rising incidence of childhood nephrotic syndrome.

The nephrotic syndrome market size is expected to see rapid growth in the next few years. It will grow to $1.58 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to advancements in targeted therapies, increasing use of precision nephrology, development of improved dialysis devices, rising investment in kidney replacement therapy innovations, growing adoption of molecular diagnostic tools. Major trends in the forecast period include rising use of immunosuppressive therapies, growing demand for advanced dialysis and kidney support devices, increasing adoption of early diagnostic screening programs, higher prevalence of chronic kidney diseases driving treatment needs, expansion of personalized medicine approaches in nephrology.

The rising prevalence of kidney diseases is expected to drive the growth of the nephrotic syndrome market in the coming years. Kidney diseases encompass conditions that impair the kidneys’ ability to filter waste and excess fluids from the blood, which is essential for maintaining overall health. Factors contributing to the increasing incidence of kidney diseases include diabetes, hypertension, obesity, aging populations, and lifestyle habits such as high sodium intake and insufficient hydration. Nephrotic syndrome plays a role in kidney disease progression by damaging the glomeruli, reducing the kidneys’ ability to retain essential proteins and filter waste effectively. For example, in June 2023, Oxford Academic, the research platform of Oxford University Press in the UK, reported that the prevalence of chronic kidney disease (CKD) in the UK is projected to rise by 4%, from 8.27 million to 8.61 million people between 2022 and 2032. The projected stage distribution for 2032 is 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Therefore, the increasing prevalence of kidney diseases is boosting the growth of the nephrotic syndrome market.

Leading companies in the nephrotic syndrome market are focusing on developing innovative formulations, such as loop diuretic injections, to improve fluid management and reduce edema in patients. Loop diuretic injections are medications that inhibit sodium and chloride reabsorption in the loop of Henle, promoting rapid urine production. They are used to treat conditions such as acute pulmonary edema, heart failure, and severe hypertension by reducing fluid overload. For example, in March 2024, Avenacy Inc., a US-based pharmaceutical company, launched furosemide for injection in the U.S., a generic equivalent to Lasix, approved by the FDA for treating edema associated with heart failure, liver cirrhosis, and kidney diseases. Packaged in 25-unit packs of 100 mg/10 mL doses, this launch is part of Avenacy’s broader strategy to expand its injectable medication portfolio, with plans to release over 20 products in 2024. The drug is indicated for both adults and pediatric patients for treating edema related to congestive heart failure, liver cirrhosis, and renal disease, including nephrotic syndrome.

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics for $3.5 billion. This acquisition aims to expand Novartis’ renal portfolio by integrating Chinook Therapeutics’ late-stage assets, including atrasentan and zigakibart, which are being developed for the treatment of Immunoglobulin A Nephropathy (IgAN). The move aligns with Novartis’ strategy to focus on innovative medicines. Chinook Therapeutics is a US-based biopharmaceutical company specializing in therapies for nephrotic syndrome.

Major companies operating in the nephrotic syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, Asahi Kasei Corporation, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Mallinckrodt Company, Evotec SE, Travere Therapeutics Inc., Aurinia Pharmaceuticals Inc., Orbis Biosciences Inc., Alpine Immune Sciences, Kezar Life Sciences, Zenyaku Kogyo Co. Ltd.

North America was the largest region in the nephrotic syndrome market in 2025. The regions covered in the nephrotic syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nephrotic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs impact the nephrotic syndrome market by increasing costs of imported dialysis machines, catheters, and diagnostic equipment essential for kidney disease management. Regions dependent on imported nephrology devices - particularly Asia-Pacific and Europe - face procurement delays and higher treatment expenses. Segments such as dialysis devices, imaging diagnostics, and drug imports are most affected. Positive effects include encouraging domestic manufacturing and boosting innovation in cost-efficient kidney care solutions.

The nephrotic syndrome market research report is one of a series of new reports that provides nephrotic syndrome market statistics, including nephrotic syndrome industry global market size, regional shares, competitors with a nephrotic syndrome market share, detailed nephrotic syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the nephrotic syndrome industry. This nephrotic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine (proteinuria), low blood protein levels (hypoalbuminemia), high cholesterol (hyperlipidemia), and swelling (edema), commonly affecting the legs, feet, and around the eyes. The condition arises from damage to the glomeruli, the kidney’s filtering units, which allows protein to leak into the urine.

The main types of nephrotic syndrome treatments include drugs and devices. Drugs are used to manage symptoms, reduce proteinuria, control blood pressure, and address underlying causes of glomerular damage. Diagnosis of nephrotic syndrome can involve urinalysis, glomerular filtration rate (GFR) measurement, blood tests, kidney biopsy, and imaging techniques such as computerized tomography (CT) scans. Treatments and diagnostic tools are applied in clinics, hospitals, specialty centers, and other healthcare facilities.

The nephrotic syndrome market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, dialysis services, and kidney transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nephrotic syndrome market also includes sales of diuretics, anticoagulants, immunosuppressants, ACE inhibitors and Arbs and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.